Liminal BioSciences Inc. Common Shares
LMNL
LMNL was delisted on the 25th of September, 2023.
16 hedge funds and large institutions have $3.21M invested in Liminal BioSciences Inc. Common Shares in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
14% more funds holding
Funds holding: 14 → 16 (+2)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
91% less capital invested
Capital invested by funds: $35.8M → $3.21M (-$32.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.09M |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$374K |
| 3 |
VF
Virtu Financial
New York
|
+$112K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$66.8K |
| 5 |
Jane Street
New York
|
+$63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$34.3M |
| 2 |
AI
Atom Investors
Austin,
Texas
|
-$207K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$147K |
| 4 |
JP Morgan Chase
New York
|
-$16.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.21K |
LMNL Hedge Fund Activity: Q4 2020 in Review
16 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Liminal BioSciences Inc. Common Shares (LMNL) for Q4 2020, worth a combined $3.21M — down 91% from $35.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LMNL positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.09M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $34.3M sold.
- 16 institutional investors held Liminal BioSciences Inc. Common Shares (LMNL) as of Q4 2020, up from 14 in Q3 2020.
- Funds reported $3.21M of Liminal BioSciences Inc. Common Shares stock for Q4 2020, down 91% quarter-over-quarter.
- 5 funds opened new Liminal BioSciences Inc. Common Shares positions in Q4 2020 and 3 closed out, a net change of +2 holders.
- The largest Liminal BioSciences Inc. Common Shares buyer in Q4 2020 was Armistice Capital, an estimated $3.09M added.
- The largest Liminal BioSciences Inc. Common Shares seller in Q4 2020 was Consonance Capital Management, an estimated $34.3M sold.
Based on aggregated 13F filings for Q4 2020.